Progress on the diagnosis and treatment of refractory leukemia
10.3760/cma.j.issn.1009-9921.2009.06.020
- VernacularTitle:难治性白血病诊治进展
- Author:
Jishi WANG
;
Yinghao LU
- Publication Type:Journal Article
- Keywords:
Refractory leukemia;
Molecular targeted therapy;
Hematopoietic stem cell transplantation
- From:
Journal of Leukemia & Lymphoma
2009;18(6):367-372
- CountryChina
- Language:Chinese
-
Abstract:
It is difficult for the patients of refractory leukemia to complete remission (CR) and long-term disease-free survival (DFS), and it was always been the hot spots of research in the field of hematologic malignancies. The diagnostic criteria of refractory leukemia were adjusted constantly at domestic and foreign, the high-risk factors about refractory leukemia were found constantly too. New molecular markers that represent mutations or gene overexpression have been identified such as FMS-like tyrosine kinase-3 and nucleophosmin,which will enhance the ability to more accurately prognosticate for patients with acute myeloid leukemia. The treatment of patients with refractory or relapsed acute myeloid leukemia remains challenging. Multiple new agents with tremendous potential were in development and clinical trials. Such as applying resistance reversal agents,enhancing molecular targeted therapy, improving the technology of hematopoietic stem cell transplantation,empoldering the new drugs, and forming a new chemotherapy program etc. Monoclonal antibodies and peptide vaccination with leukemia-associated antigens also brought the hopes of increasing the remission and cure rates for patients with acute myeloid leukemia.
